89Zr-DFO-REGN5054

N/A

Report date: 2025/09/24 14:01:36

Base Information

Drug Name89Zr-DFO-REGN5054

Drug Alias Name89Zr˗DFO˗REGN-505489Zr-DFO-REGN5054

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyDiagnostic agent (In vivo)Radiation-emitting products > Nuclides > Zirconium > 89Zr +[5]

Mechanisms of ActionPositron-emission tomography enhancersAnti-Cluster of differentiation 8

TargetsCluster of differentiation 8

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesRegeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A